AHR and non-small cell lung carcinoma: Using this approach, we found that K-RasG12D/+;Ahr−/− mice developed NSCLC with higher burdens (Figure 1A,B) and shorter latencies (Figure 1C) than their single K-RasG12D/+ counterpart controls, with lesions evident at 12 weeks of age.